A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
about
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and UveitisHeterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitisEmerging drugs for diabetic retinopathy.Extraintestinal manifestations and complications in inflammatory bowel diseases.An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Pharmacotherapy for uveitis: current management and emerging therapy.Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome?Management and clinical outcome of penetrating keratoplasty for long-term corneal changes in sympathetic ophthalmia.Contrasting ocular effects of local versus systemic endotoxin.Why HLA-B27? My thirty-year quest: the Friedenwald lectureEfficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patientsRetention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye diseaseEfficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patientsAdalimumab in the therapy of uveitis in childhoodCorrelation between Fluorescein Angiographic Findings and Visual Acuity in Behçet Retinal Vasculitis.Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.Vitreous analysis in the management of uveitisTumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.Adalimumab for sight-threatening uveitis in Behçet's disease.Biologic therapies for inflammatory eye disease.Drug-induced uveitisBiologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.Targeting Endothelial Adhesion Molecule Transcription for Treatment of Inflammatory Disease: A Proof-of-Concept Study.A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis.Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?Infliximab for the treatment of active scleritis.Birdshot uveitis: current and emerging treatment optionsUpdate on the use of systemic biologic agents in the treatment of noninfectious uveitis.A review and update on orphan drugs for the treatment of noninfectious uveitisClinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Emerging biologics in the treatment of uveitis.Clinical experience with adalimumab in the treatment of ocular Behçet disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Road to remission: a comprehensive review of therapy in uveitis.Biological agents for the treatment of uveitis.Biologic agents in inflammatory eye disease.Light on the horizont: biologicals in Behçet uveitis.The role of biologic agents in the management of non-infectious uveitis.Susceptibility genes and pharmacogenetics in ocular inflammatory disorders.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.
P2860
Q22299388-D5BD6DB0-94C6-4EEA-BAAB-82A7D0B97BB8Q26796779-9E5E0B91-4B1E-486D-92E3-D2959F520432Q33388498-C4BE05EB-DA7E-4971-BF2C-A9224D63BAE3Q33866998-5DC94149-F06C-44C8-A03A-71F3B5ACD2D5Q33910781-4835E682-D1B0-4612-8980-3706E63164EBQ34274075-D84A737B-AA04-482E-89AC-427EDBD1AA7DQ35065315-4881E9D7-13B3-4B03-AA20-88EF5A908854Q35104653-372B5D72-69E7-46C2-86C8-99C9C6E58EB0Q35221155-32D0B654-4E5B-4D85-AC2E-DF1FB8D29C98Q35247749-8883C8A0-D728-4DD0-B940-40C0EA4345BCQ35699360-01E0ACA4-23F6-433C-B6CF-79737EF3BAA8Q35762819-153240F3-C265-4199-B7EF-19139109E4D9Q35763133-3406D1BD-833B-4D5E-8CC5-86ED5AC00AA0Q35763157-BA1BC186-F621-4A56-8AF2-D1CA88FC8806Q35778203-AA56736C-CFB3-4E21-B3A6-8F7BF97AFF53Q36174993-C2B8FB7D-B2A3-41BE-92C5-443BE5F4A375Q36369359-C8D8C376-7578-4663-AB5F-04CC784D914CQ36388536-4ADD368F-0A42-4A67-90AF-3309D515AD85Q36443513-C8623A2D-0A74-4288-AF6D-E0429D489368Q36501675-0F43BCB6-BB07-4B5F-BEA3-D1EB9C87378BQ36797491-AA0DBD8C-0D89-499E-BCF4-00689CA8274BQ36849136-7436974F-7A92-4ED7-B7A6-62E7ED536033Q36946277-A4E8F322-7802-4DA0-8967-1CC154CD364EQ36952770-3643EF6A-414C-4C7A-AA17-4FAA2E1A3EC6Q36964382-C77C16BC-3331-4F21-A2B2-C852CFDCFFBEQ37407155-77149AA3-C209-4AB9-BF0D-E0ED9EB6BC2AQ37412317-664C8C0D-FB6A-4439-8D5B-FF73A3F615C9Q37600483-099F96BF-63B4-4656-857B-7609F94A7B5CQ37632096-06FCB443-550F-41CD-BE86-05C03761A65EQ37650221-8F2EE355-56D7-4BC9-B6D3-F9069829D7C8Q37754665-0ADDD857-0534-4643-8DBE-7C7B45A3FCC9Q37756167-3550CEEC-94F5-4084-AE44-9F1C2990D7A0Q37820898-7C638682-0EEE-42D6-A1E0-623BA1158D55Q37936459-F8545392-F7E0-4EBE-813E-354FE255D3A4Q37984565-5B0071E4-F082-4282-84FF-23606746BE62Q37997772-861A9709-7022-4170-8B79-79E2B97EC1AFQ38004097-2991D4C6-7A45-444E-93AA-B30D53934A7BQ38025152-2310E4F7-D191-4BDE-ABCE-EA57831DF80DQ38043013-DB7185FF-3977-442C-98EC-F4E47CBFF18FQ38074446-D8F5FF11-D847-4EEA-9810-E1E821BB35E4
P2860
A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A prospective trial of inflixi ...... safety and efficacy outcomes.
@en
A prospective trial of inflixi ...... safety and efficacy outcomes.
@nl
type
label
A prospective trial of inflixi ...... safety and efficacy outcomes.
@en
A prospective trial of inflixi ...... safety and efficacy outcomes.
@nl
prefLabel
A prospective trial of inflixi ...... safety and efficacy outcomes.
@en
A prospective trial of inflixi ...... safety and efficacy outcomes.
@nl
P2093
P1433
P1476
A prospective trial of inflixi ...... y safety and efficacy outcomes
@en
P2093
Andreas K Lauer
Daryl E Kurz
Eric B Suhler
James T Rosenbaum
Michael S Wertheim
Terri D Pickard
P304
P356
10.1001/ARCHOPHT.123.7.903
P407
P577
2005-07-01T00:00:00Z